Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

Secretary of the Senate
Received: Feb 14, 2007

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

GENZYME CORP

2. Address:
1020 19TH ST NW #550, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: MARY MCGRANE
Telephone: 2022963280
E-mail (optional): mary.mcgrane@genzyme.com

Senate ID #: 16054-12
House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000: ☐

$10,000 or more: ☐ => Income (nearest $20,000):_____

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than $10,000: ☐

$10,000 or more: ☒ => Expenses (nearest $20,000): 1,231,846.00

14. Reporting Method.
Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☒ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

a) Regulatory framework affecting generic biologics. b) Patent reform issues. c) H.R. 2795, "The Patent Reform Act of 2005". d) Process patents.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH
Covered Official Position (if applicable): N/A
Name: HOLCOMBE, KAY
Covered Official Position (if applicable): N/A
Name: MCGRANE, MARY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

a) Reimbursement for clinical lab services under Medicare. b) H.R. 5369, "Advanced Laboratory Diagnostics Act of 2006". c) S. 3822, "Genomics & Personalized Medicine Act of 2006". d) H.R. 6408, "Tax Relief and Health Care Act of 2006".

17. House(s) of Congress and Federal agencies contacted:
Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH
Covered Official Position (if applicable): N/A
Name: HOLCOMBE, KAY
Covered Official Position (if applicable): N/A
Name: MCGRANE, MARY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

c) Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician offices. d) Implementation of the Competitive Acquisition (CAP) Program for Part B Drugs. e) 340B Programs. f) H.R. 4241, "Deficit Reduction Act of 2005". g) S. 1932, "Deficit Reduction Omnibus Reconciliation Act of 2005". h) CMS guidance on coverage under evidence development. i) Physicians fee schedule payment rates for lab tests. j) Medicaid budget reductions. k) H.R. 6408, "Tax Relief and Health Care Act of 2006". l) Medicaid rebates a) Medicare Prescription Drug Benefit: Implementation of issues associated w/P.L. 108-173, including reimbursement for orphan drugs. b) HCPCS Workgroup Coding Decisions.

17. House(s) of Congress and Federal agencies contacted:
Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH
Covered Official Position (if applicable): N/A
Name: HOLCOMBE, KAY
Covered Official Position (if applicable): N/A
Name: MCGRANE, MARY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

e) S. 109, "Pharmaceutical Market Access Act of 2005". f) S. 334, "Pharmaceutical Market Access & Drug Safety Act of 2005". g) Issues related to clinical trial data bank. h) S. 470, H.R. 3196, "Fair Access to Clinical Trials Act". i) H.R. 6257, "Access to Life-Saving Medicines Act". a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.930, "Food & Drug Administration Act of 2005". c) H.R. 2090, "Food & Drug Administration Improvement Act of 2005". d) H.R. 700, "Pharmaceutical Market Access & Drug Safety Act of 2005" - Importation.

17. House(s) of Congress and Federal agencies contacted:
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH
Covered Official Position (if applicable): N/A
Name: HOLCOMBE, KAY
Covered Official Position (if applicable): N/A
Name: MCGRANE, MARY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

Tax incentives for neglected disease research.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MCGRANE, MARY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: MARY MCGRANE, SENIOR VICE PRESIDENT, GOVERNMENT RE -